title: [Prevention of skeletal related events in patients with bone metastases from solid tumours].
abstract: This article is based on a systematic literature search and meta-analyses of clinical data regarding effects of bisphosphonates (BP) and denosumab (DS) on preventing skeletal related events (SRE) in patients with bone metastases from solid tumours. Although there are pharmacological differences between the different types of BP no major differences were observed between BP in preventing SRE or in adverse events. Treatment with DS has in three randomised trials showed a greater effect than BP in preventing SRE. The optimal choice of bone-anti-resorptive agent should depend on the patient's general condition, renal function and treatment logistics.
authors.affiliation: Onkologisk Klinik, Finsencenteret, Rigshospitalet. claus.kamby@regionh.dk.
authors.forename: Claus
authors.initials: C
authors.lastname: Kamby
authors.forename: Simon
authors.initials: S
authors.lastname: Tarp
authors.forename: Anders
authors.initials: A
authors.lastname: Mellemgaard
authors.forename: Robin
authors.initials: R
authors.lastname: Christensen
authors.forename: Søren
authors.initials: S
authors.lastname: Cold
authors.forename: Pia
authors.initials: P
authors.lastname: Eiken
authors.forename: Erik Hugger
authors.initials: EH
authors.lastname: Jakobsen
authors.forename: Niels Christian
authors.initials: NC
authors.lastname: Langkilde
authors.forename: Sven Tyge
authors.initials: ST
authors.lastname: Langkjer
authors.forename: Torben
authors.initials: T
authors.lastname: Laursen
authors.forename: Svend Saalbach
authors.initials: SS
authors.lastname: Ottesen
authors.forename: Anita Gorm
authors.initials: AG
authors.lastname: Pedersen
authors.forename: Lars Eric
authors.initials: LE
authors.lastname: Stenbygaard
authors.forename: Peter Michael
authors.initials: PM
authors.lastname: Vestlev
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D000069448:Denosumab / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D015201:Meta-Analysis as Topic; D011471:Prostatic Neoplasms / Q000473:pathology; D011859:Radiography
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab